Table 4. Case reports of novel therapies in advanced pancreatic cancer.

Aberration	Histology	Agent	Line	Outcome	Rationale for Agent	Reference
PALB2 Mutation	Adenocarcinoma	Mitomycin C	2nd	Partial Response	Patient's tumor xenograft demonstrated sensitivity to mitomycin C	Villarroel et al, 2011 [46]
BRCA2 Mutation	Adenocarcinoma	Mitomycin C + Capecitabine	3rd	Partial Response	Pre-clinical data with mitomycin C in BRCA2 cell lines and prior published responses to mitomycin C	Chalasani et al, 2008 [47]
STK11/LKB1 Mutation	Acinar Cell Carcioma	Everolimus	1st	Partial Response	Loss of mTOR inhibition with STK11/LKB1 mutation	Klumpen et al, 2011 [50]